v3.25.0.1
Net Loss Per Share (Tables)
 3 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following table presents the computation of basic and diluted net loss per share.
Three Months Ended December 31,
20242023
(in thousands, except per share amounts)
Numerator:
Net loss attributable to Arrowhead Pharmaceuticals, Inc.$(173,085)$(132,864)
Denominator:
Weighted-average basic shares outstanding (1)
124,848 107,415 
Effect of dilutive securities— — 
Weighted-average diluted shares outstanding (1)
124,848 107,415 
Basic net loss per share$(1.39)$(1.24)
Diluted net loss per share$(1.39)$(1.24)
(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following table sets forth the potentially dilutive securities that have been excluded from the calculation of
diluted net loss per share because to include them would be anti-dilutive.
Three Months Ended December 31,
20242023
(in thousands)
Options739 718 
Restricted stock units3,845 2,826 
Total4,584 3,544